Used as a key intermediate in the synthesis of trelagliptin, an antidiabetic drug belonging to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It plays a critical role in enhancing the stability and pharmacokinetic profile of the final active pharmaceutical ingredient. Its fluorinated aromatic structure contributes to improved metabolic resistance and target binding affinity, making it valuable in the development of once-weekly oral medications for type 2 diabetes. The compound is primarily utilized in controlled laboratory and industrial settings during the late-stage assembly of the drug substance.